Clinical Scorecard: Exploring the Range of Tendon Toxicity Linked to Anastrozole, Letrozole, and Exemestane: Insights from a Real-World Pharmacovigilance Analysis
At a Glance
Category
Detail
Condition
Tendon disorders associated with aromatase inhibitors
Key Mechanisms
Estrogen deprivation leading to alterations in tendon structure and function
Target Population
Postmenopausal women with hormone receptor-positive breast cancer
Care Setting
Clinical practice involving breast cancer treatment
Key Highlights
Positive signals for tendon disorders linked to third-generation aromatase inhibitors identified.
Letrozole showed the earliest onset of tendon disorders at 74 days.
Exemestane exhibited the latest onset at 243.5 days.
Tendon disorders include trigger finger and tenosynovitis stenosans.
Clear association between third-generation aromatase inhibitors and tendon disorders observed.
Guideline-Based Recommendations
Diagnosis
Monitor for tendon disorders in patients receiving aromatase inhibitors.
Management
Consider alternative therapies if significant tendon disorders develop.
Monitoring & Follow-up
Regular assessment of musculoskeletal symptoms in patients on aromatase inhibitors.
Risks
Increased risk of tendon disorders, including tendonitis and tendon rupture.
Patient & Prescribing Data
Postmenopausal women with hormone receptor-positive breast cancer
Aromatase inhibitors are effective but carry risks of musculoskeletal adverse events.
Clinical Best Practices
Educate patients about potential musculoskeletal side effects of aromatase inhibitors.
Implement early intervention strategies for managing tendon disorders.
Ensure regular follow-up to monitor for signs of tendon toxicity.
